skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration
Indication-based pricing isn’t just coming. It’s here. Drug companies have historically priced drugs equally across indications, regardless of the variation in value. But using indication-specific pricing, payers – and PBMs in particular – see a new opportunity to break the market-share dominance of several key therapeutics, boost their near-term rebate and distribution income, and re-shape traditional contracting.

Indication-Based Pricing

Download your free article pack, to discover new insights into indication-based pricing
Market access_RxScorecard_Pharmaintelligence

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: